ID

34411

Beschrijving

Non-interventional Study With Pomalidomide (Imnovid®); ODM derived from: https://clinicaltrials.gov/show/NCT02075996

Link

https://clinicaltrials.gov/show/NCT02075996

Trefwoorden

  1. 17-01-19 17-01-19 -
Houder van rechten

see on clinicaltrials.gov

Geüploaded op

17 januari 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Multiple Myeloma NCT02075996

Eligibility Multiple Myeloma NCT02075996

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with relapsed or refractory multiple myeloma patients must have received at least two prior lines of treatment (induction therapy followed by stem cell transplantation ± maintenance therapy is considered one prior therapy) and must have progressed under the most recent therapy regimen
Beschrijving

ID.1

Datatype

boolean

adult male and female patients (at least 18 years with no upper age limit)
Beschrijving

ID.2

Datatype

boolean

written informed consent to data collection and pseudonymized data transfer
Beschrijving

ID.3

Datatype

boolean

the conditions of the pregnancy prevention programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics imnovid®)
Beschrijving

ID.4

Datatype

boolean

other criteria according to summary of product characteristics imnovid®
Beschrijving

ID.5

Datatype

boolean

Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
missing patient's informed consent
Beschrijving

ID.6

Datatype

boolean

pregnant or breast-feeding women
Beschrijving

ID.7

Datatype

boolean

male patients, not capable of complying the required preventive measures (see summary of product characteristics imnovid®)
Beschrijving

ID.8

Datatype

boolean

other criteria according to summary of product characteristics imnovid®
Beschrijving

ID.9

Datatype

boolean

Similar models

Eligibility Multiple Myeloma NCT02075996

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with relapsed or refractory multiple myeloma patients must have received at least two prior lines of treatment (induction therapy followed by stem cell transplantation ± maintenance therapy is considered one prior therapy) and must have progressed under the most recent therapy regimen
boolean
ID.2
Item
adult male and female patients (at least 18 years with no upper age limit)
boolean
ID.3
Item
written informed consent to data collection and pseudonymized data transfer
boolean
ID.4
Item
the conditions of the pregnancy prevention programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics imnovid®)
boolean
ID.5
Item
other criteria according to summary of product characteristics imnovid®
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
missing patient's informed consent
boolean
ID.7
Item
pregnant or breast-feeding women
boolean
ID.8
Item
male patients, not capable of complying the required preventive measures (see summary of product characteristics imnovid®)
boolean
ID.9
Item
other criteria according to summary of product characteristics imnovid®
boolean

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial